LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (TKAI) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Tokai shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The investigation is related to a July 26, 2016 announcement that Tokai would end a late-stage trial of its prostate cancer therapy candidate, galeterone, saying that it believed the phase 3 study would not meet its primary endpoint. When this announcement was made public, Tokai shares fell in value.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.